IL17A and ovarian carcinoma: Recently, however, it has been reported that the levels of Th17 cells and the levels of IL-17A in ascites were reduced in more advanced diseases and positively predicted patient outcome in human ovarian cancer because Th17 cells contributed to anti-tumor immunity [15].